127 related articles for article (PubMed ID: 20210803)
1. SPARC (osteonectin) in breast tumors of different histologic types and its role in the outcome of invasive ductal carcinoma.
Hsiao YH; Lien HC; Hwa HL; Kuo WH; Chang KJ; Hsieh FJ
Breast J; 2010; 16(3):305-8. PubMed ID: 20210803
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients.
Nagai MA; Gerhard R; Fregnani JH; Nonogaki S; Rierger RB; Netto MM; Soares FA
Breast Cancer Res Treat; 2011 Feb; 126(1):1-14. PubMed ID: 20369286
[TBL] [Abstract][Full Text] [Related]
3. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma.
Di Saverio S; Gutierrez J; Avisar E
Breast Cancer Res Treat; 2008 Oct; 111(3):541-7. PubMed ID: 18026874
[TBL] [Abstract][Full Text] [Related]
4. Is survival from infiltrating lobular carcinoma of the breast different from that of infiltrating ductal carcinoma?
Jayasinghe UW; Bilous AM; Boyages J
Breast J; 2007; 13(5):479-85. PubMed ID: 17760669
[TBL] [Abstract][Full Text] [Related]
5. The Yale University experience of early-stage invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) treated with breast conservation treatment (BCT): analysis of clinical-pathologic features, long-term outcomes, and molecular expression of COX-2, Bcl-2, and p53 as a function of histology.
Moran MS; Yang Q; Haffty BG
Breast J; 2009; 15(6):571-8. PubMed ID: 19995377
[TBL] [Abstract][Full Text] [Related]
6. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes.
Watkins G; Douglas-Jones A; Bryce R; Mansel RE; Jiang WG
Prostaglandins Leukot Essent Fatty Acids; 2005 Apr; 72(4):267-72. PubMed ID: 15763438
[TBL] [Abstract][Full Text] [Related]
7. Expression and clinical significance of SPARC in clinical stage II tongue squamous cell carcinoma.
Zhang J; Zhang Q; Zhang Q; Liu XK; Li CQ; Guo ZM
Ai Zheng; 2009 Jan; 28(1):68-71. PubMed ID: 19448421
[TBL] [Abstract][Full Text] [Related]
8. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma.
Sanlioglu AD; Korcum AF; Pestereli E; Erdogan G; Karaveli S; Savas B; Griffith TS; Sanlioglu S
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):716-23. PubMed ID: 17512128
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression.
Yamashita K; Upadhay S; Mimori K; Inoue H; Mori M
Cancer; 2003 May; 97(10):2412-9. PubMed ID: 12733139
[TBL] [Abstract][Full Text] [Related]
10. Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma.
Cho MH; Yoon JH; Jaegal YJ; Choi YD; Lee JS; Lee JH; Nam JH; Choi C; Lee MC; Park CS; Woo Juhng S; Min KW
Breast; 2006 Jun; 15(3):390-8. PubMed ID: 16169726
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of molecular classification of breast invasive ductal carcinoma.
Muñoz M; Fernández-Aceñero MJ; Martín S; Schneider J
Arch Gynecol Obstet; 2009 Jul; 280(1):43-8. PubMed ID: 19082617
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of proliferating cell nuclear antigen (PCNA) in infiltrating ductal carcinoma breast.
Aziz SA; Pervez S; Khan SM; Kayani N; Nasir MI
J Coll Physicians Surg Pak; 2005 Apr; 15(4):225-9. PubMed ID: 15857596
[TBL] [Abstract][Full Text] [Related]
13. Tumor characteristics and patient outcomes are similar between invasive lobular and mixed invasive ductal/lobular breast cancers but differ from pure invasive ductal breast cancers.
Bharat A; Gao F; Margenthaler JA
Am J Surg; 2009 Oct; 198(4):516-9. PubMed ID: 19800459
[TBL] [Abstract][Full Text] [Related]
14. Outcome after breast-conserving therapy for patients with stage I or II mucinous, medullary, or tubular breast carcinoma.
Thurman SA; Schnitt SJ; Connolly JL; Gelman R; Silver B; Harris JR; Recht A
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):152-9. PubMed ID: 15093911
[TBL] [Abstract][Full Text] [Related]
15. Cysteine proteinase inhibitor cystatin A in breast cancer.
Kuopio T; Kankaanranta A; Jalava P; Kronqvist P; Kotkansalo T; Weber E; Collan Y
Cancer Res; 1998 Feb; 58(3):432-6. PubMed ID: 9458085
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
[TBL] [Abstract][Full Text] [Related]
17. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
18. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma.
Infante JR; Matsubayashi H; Sato N; Tonascia J; Klein AP; Riall TA; Yeo C; Iacobuzio-Donahue C; Goggins M
J Clin Oncol; 2007 Jan; 25(3):319-25. PubMed ID: 17235047
[TBL] [Abstract][Full Text] [Related]
19. Inhibin/activin subunits (inhibin-alpha, -betaA and -betaB) are differentially expressed in human breast cancer and their metastasis.
Mylonas I; Jeschke U; Shabani N; Kuhn C; Friese K; Gerber B
Oncol Rep; 2005 Jan; 13(1):81-8. PubMed ID: 15583806
[TBL] [Abstract][Full Text] [Related]
20. [Expression and intranuclear distribution of nucleolin in estrogen receptor-negative and estrogen receptor-positive breast cancers in women measured by laser scanning cytometry].
Masiuk M
Ann Acad Med Stetin; 2006; 52(2):23-32. PubMed ID: 17633394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
